YM BioSciences Initiates Patient Enrolment In Phase II Colorectal Cancer Trial With EGFR Antibody MISSISSAUGA, ON, July 31 /CNW/ - YM BioSciences...
YM BIOSCIENCES ANNOUNCES SECONDARY EFFICACY AND SAFETY FINDINGS IN RANDOMIZED PHASE IIB AEROLEF(TM) TRIAL - Company Announces Lead Investigator...
YM BioSciences announces preclinical data confirming nimotuzumab binds to the EGF receptor and potentiates radiotherapy MISSISSAUGA, ON, July 9...
YM BioSciences Receives FDA Clearance for an IND for its Fentanyl-Based Pain Product AeroLEF(TM) - YM to initiate trial in the U.S. and plans End...
Attention Business Editors: YM BioSciences Cleared to Initiate Clinical trial of Nimotuzumab in Children with inoperable recurrent Brain Cancer...
YM BioSciences Cleared to Initiate Clinical trial of Nimotuzumab in colorectal Cancer MISSISSAUGA, ON, June 4 /CNW/ - YM BioSciences Inc...
YM BioSciences reports successful regulatory reviews of nimotuzumab manufacturing MISSISSAUGA, ON, May 24 /CNW/ - YM BioSciences Inc. (AMEX:YMI...
YM BioSciences reports third quarter 2007 operational and financial results MISSISSAUGA, ON, May 11 /CNW/ - YM BioSciences Inc. (AMEX:YMI, TSX:YM...
YM BioSciences Reports AeroLEF(TM) Randomized Phase IIb Trial Meets Primary Endpoint in Patients with Post-Surgical Pain MISSISSAUGA, ON, May 2...
YM BioSciences' partner Daiichi Sankyo receives clearance for initial clinical trial in Japan MISSISSAUGA, ON, and TOKYO, Japan, April 16 /CNW/...
YM BioSciences Strengthens Program Management of Lead Drugs Appointment of John Waterfall, Ph.D. MISSISSAUGA, ON, April 3 /CNW/ - YM BioSciences...
YM BioSciences completes enrolment of AeroLEF(TM) Phase IIB pain trial - AeroLEF(TM) to be presented at Oppenheimer Pain Management Conference...
Attention Business Editors: YM BioSiences announces management changes MISSISSAUGA, ON, Feb. 12 /CNW/ - YM BioSciences Inc. (AMEX:YMI, TSX:YM...
YM Biosciences Reports Second Quarter 2007 Operational and Financial Results MISSISSAUGA, ON, Feb. 9 /CNW/ - YM BioSciences Inc. (AMEX:YMI...
YM BioSciences announces termination of the tesmilifene Phase III pivotal trial in advanced breast cancer - The Data Safety Monitoring Board...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.